Here are the 10-K annual reports from Accuray Incorporated (ARAY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ARAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARAY filings page.
Accuray Inc (ARAY) provides radiation therapy systems and software, centered on its CyberKnife robotic platform and a differentiated helical portfolio (Accuray Stellar, Radixact, Accuray Helix and Tomo C). These systems support SRS, SBRT, IMRT, IGRT and adaptive radiotherapy, aiming for precise dose delivery while managing exposure to healthy tissue.
The company also offers treatment planning (Accuray Precision), data management (iDMS), motion tracking (Synchrony), advanced imaging (ClearRT), and workflow/QA tools, plus installation, training and services to build recurring revenue. Strategy focuses on clinical adoption, international expansion, joint ventures (including a China JV for Tomo C), and AI-enabled service tools while improving cost efficiency and supply chain resilience.
Accuray operates under extensive U.S. and international medical device and healthcare regulations, with all current products cleared as Class II devices in the U.S. It reports holding hundreds of patents supporting its technology position and emphasizes ongoing R&D collaborations and talent development to sustain innovation.
Accuray Incorporated filed an amended Annual Report to restate its disclosure of remaining performance obligations (RPO) after discovering significant errors in how open system orders, upgrades and customer credits were classified under ASC 606. RPO balances were reduced to $60.9 million from $818.2 million as of June 30, 2025, with similar large reductions for prior quarters. The company states these errors did not affect its balance sheets, income statements or cash flow statements. Management and the audit committee concluded prior financial statements for the affected periods should no longer be relied upon, and internal control over financial reporting and disclosure controls were not effective due to material weaknesses in review of footnote schedules and ASC 606 judgments.